RNF213 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the RNF213 protein. RNF213, also known as ring finger protein 213, is a large multidomain protein that plays a crucial role in various cellular processes, particularly in vascular development and angiogenesis. The inhibitors of RNF213 function by binding to the protein and obstructing its enzymatic activity, which primarily involves E3 ubiquitin ligase activity. This inhibition can lead to altered cellular signaling pathways, especially those related to vascular development and maintenance. The molecular structure of RNF213 inhibitors is characterized by their ability to interact with the specific domains of RNF213, such as the RING finger domain, which is critical for its ubiquitin ligase activity.
RNF213 inhibitors are diverse, yet they share common structural features that enable them to effectively bind to RNF213. These features include specific functional groups or motifs that facilitate the interaction with key amino acid residues of RNF213. This interaction is crucial for the inhibition as it disrupts the protein's normal function. The inhibitors are typically small molecules, designed to penetrate cellular membranes easily and reach intracellular targets. The exact mechanism of inhibition can vary among different inhibitors; some may directly block the active site of the protein, while others might induce conformational changes that reduce its activity. The specificity of these inhibitors towards RNF213 is of paramount importance, as it ensures minimal off-target effects and maximizes the efficiency of inhibition. The development and study of RNF213 inhibitors have provided significant insights into the molecular functions of RNF213 and its role in cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a tyrosine kinase inhibitor that indirectly affects RNF213 activity by targeting angiogenic processes. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a kinase inhibitor, modulates pathways associated with angiogenesis, indirectly influencing RNF213 function. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib is an angiogenesis inhibitor targeting multiple tyrosine kinases, thereby affecting RNF213-related pathways. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib, an EGFR inhibitor, can indirectly impact RNF213 through the modulation of growth factor signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib targets tyrosine kinases involved in angiogenesis, indirectly affecting RNF213's role in vascular development. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, a broad-spectrum tyrosine kinase inhibitor, may influence RNF213 activity by altering angiogenic signaling. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib, another tyrosine kinase inhibitor, can indirectly modulate RNF213 function through vascular signaling pathways. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib, targeting VEGFR, indirectly affects RNF213 through its role in angiogenesis and vascular development. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Regorafenib, a multi-kinase inhibitor, indirectly modulates RNF213 activity through angiogenic and vascular signaling. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
Cabozantinib, targeting MET and VEGFR2, indirectly affects RNF213 by influencing angiogenic signaling. | ||||||